TTrialPathMatch Me to Trials
← Back to trials
RecruitingRenal Insufficiency, Chronic

Neurovascular Transduction During Exercise in Chronic Kidney Disease

Eligible age

18–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.

Sponsor: Emory University

You may qualify if…

  • ✓ Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  • ✓ Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months
  • ✓ Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
  • ✓ Willing and able to cooperate with the study protocol
  • ✓ Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
  • ✓ Willing and able to cooperate with the study protocol

You may not qualify if…

  • ✕ severe CKD (eGFR\<15 cc/minute)
  • ✕ ongoing drug or alcohol abuse
  • ✕ diabetic neuropathy
  • ✕ any serious systemic disease that might influence survival
  • ✕ severe anemia with hgb level \<9 g/dL
  • ✕ clinical evidence of congestive heart failure or ejection fraction below 35%
  • ✕ symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history
  • ✕ treatment with central alpha agonists (clonidine)

Where it's recruiting

Georgia

Atlanta · Decatur

Source: ClinicalTrials.gov · NCT02947750 · last updated 2026-05-18